BRD4標靶治療市場：市場機會、技術平台、發展趨勢與臨床試驗洞察（2026年）

「BRD4標靶治療市場－市場機會、技術平台、發展趨勢與臨床試驗洞察（2026）」報告的主要發現與亮點：

• 首個標靶治療預計將於 2030 年獲得批准。
• BRD4 成為博弈的主要目標。
• 對標靶BRD4的新型治療策略進行全面分析。
• BRD4標靶治療臨床試驗的啟示：目前有超過20種療法正在進行試驗。
• 全球 BRD4標靶治療，依公司、適應症及臨床試驗階段分類。
• 領先的下一代 BRD4 療法技術和藥物發現平台。
• 競爭格局

BRD4標靶治療的必要性及本報告的意義

標靶BRD4的療法是表觀遺傳藥物研發和精準腫瘤學領域發展最快、最有前景的子領域之一。Bromodomain結構域蛋白4 (BRD4) 作為控制腫瘤生長、增殖、轉移、免疫反應和治療抗藥性的關鍵轉錄調節因子，是多種癌症治療中極具潛力的標靶。與目前調控特定訊號路徑的癌症藥物標靶不同，BRD4作為轉錄樞紐，在統籌腫瘤的主要致癌性轉錄程序中發揮至關重要的作用，包括MYC介導的基因表現和超級增強子功能。

針對 BRD4的標靶治療研發路徑已從第一代泛 BET 抑制劑發展到更複雜、更具選擇性的策略，旨在提高療效和持久性。這包括透過新型機制高精度靶向Bromodomain以誘導基因靜默的策略，例如選擇性 BRD4 抑制劑、Bromodomain特異性分子、共用和變構 BRD4 抑制劑、靶向蛋白水解劑以及聯合治療。

本報告對BRD4標靶治療的演變整體情況進行了全面分析，包括科學證據、藥物研發方法、最新臨床趨勢、新技術、競爭格局和未來商業性前景。報告為投資者和製藥公司提供了寶貴的見解，幫助他們識別新興BRD4標靶治療市場中的關鍵市場機會、新技術、競爭格局以及投資、合作和產品組合開發機會。

本報告中包含對臨床試驗的深入分析

臨床開發在評估BRD4標靶治療的潛力方面發揮著至關重要的作用。儘管目前尚無已通過核准的BRD4標靶療法，但許多候選藥物已完成或正在進行各種急性骨髓性白血病和固體癌的臨床試驗。本報告分析了目前正在研發中的BRD4和BET抑制劑標靶候選標靶治療，以及處於早期和後期臨床試驗階段的候選藥物，這些藥物針對的疾病包括急性髓系白血病、骨髓纖維化、淋巴瘤、兒童癌、兒童癌症和固體癌。

本報告全面闡述了針對BRD4的最新臨床試驗和研究成果，涵蓋了廣泛的適應症、患者群體、臨床分期和治療方法。報告分析了BRD4單藥療法，以及聯合治療，重點在於BRD4標靶藥物與表觀遺傳藥物、凋亡誘導劑、激酶抑制劑、DNA修復療法和免疫療法的聯合應用。此外，報告還介紹了進行相關研究的機構，例如製藥公司、生物製藥公司和學術機構，使讀者能夠清晰整體情況BRD4標靶治療的資助者概況。

領先企業積極參與BRD4標靶治療的研發

從治療角度來看，BRD4涉及眾多製藥和生物技術公司，以及參與開發針對BRD4標靶藥物的研究機構，這些藥物涵蓋多個治療領域。早期藥物研發主要由致力於BET抑制劑研發的公司主導。例如，perabrecib、PLX2853、BMS-986158和ABBV-075等計畫的發展就體現了這一點，這些計畫促進了血液學和腫瘤學領域BRD4抑制相關臨床知識的累積。這些早期計畫奠定了BRD4的臨床意義，並為選擇性標靶和下一代標靶療法的開發鋪平了道路。

目前競爭格局主要由多家公司主導，這些公司致力於開發針對BRD4的新型策略，包括選擇性BRD4抑制劑、BRD4蛋白分解以及聯合治療。這些生物技術公司包括Halda Therapeutics、DeepCure和Model Medicines。此外，學術機構也正在透過發現與BRD4相關的新型調控機制和治療機會，為此競爭格局做出貢獻。越來越多的參與企業BRD4藥物研發領域，進行合作研究，以及製藥公司的投資，都顯示了這種藥物研發方法的商業性潛力。

技術平台、合作夥伴關係和協議

技術進步正推動著非常規療法的探索，這些療法利用各公司開發的平台，以更具選擇性和永續的方式靶向目標生物體。這些創新療法包括蛋白水解分解（例如 PROTAC 和分子黏合劑）、人工智慧驅動的藥物發現、RNA定序以及化合物的精準遞送。例如，Halda Therapeutics 的 RIPTAC™ 技術是一個創新平台，旨在抑制癌細胞內關鍵的癌症相關蛋白質功能，該公司正在開發一種名為 HLD-0915 的產品，用於治療前列腺癌。這些平台旨在克服傳統 BET 抑制劑的局限性，並開發下一代基於 BRD4 的療法。

生物技術公司、製藥公司和學術研究機構之間的合作持續推動著該領域的創新。旨在促進蛋白水解、人工智慧驅動的藥物發現、生物標記識別以及精準遞送技術開發的合作，正在拓展基於BRD4的療法的潛在應用。本報告評估了塑造BRD4標靶治療未來發展的關鍵技術進展、夥伴關係、授權授權和平台策略。

一份概述BRD4標靶治療未來方向的報告。

提高標靶治療的精準度、探索新的作用機制以及拓展適應症將是未來BRD4標靶治療的關鍵主題。下一代靶向BRD4或特定Bromodomain的抑制劑有望開闢新的治療窗口，而分解技術則可能進一步增強抑制BRD4調控的轉錄程序的能力。聯合治療也可能在BRD4標靶治療的發展中發揮至關重要的作用，有望與傳統抗癌藥物形成互補，並克服抗藥性機制。

隨著對BRD4生物學特性的理解不斷加深，其應用範圍已超越腫瘤學領域，BRD4標靶療法有望在發炎性疾病、心血管疾病、感染疾病以及其他以轉錄調控異常為特徵的疾病中開闢新的應用前景。基於生物標記的患者篩選、先進的藥物遞送技術和新型治療平台的融合將決定BRD4研發的未來方向。本報告對這些機會進行了全面評估，並深入分析了BRD4標靶療法的科學進展、商業性潛力和未來發展前景。

目錄

第1章：調查方法

第2章：BET家族與BRD4標靶化概述

• 表觀遺傳藥物標靶概述
• BET蛋白家族的生物學與功能
• 利用BET蛋白作為治療標靶
• BRD4 成為主要的投注目標。
• BRD4標靶治療的歷史發展

第3章：標靶BRD4的生物學證據

• BRD4 結構和結構域配置
• BRD4的生物學功能
• BRD4在基因調控中的作用
• BRD4在癌症特徵中的作用

第4章：針對BRD4的治療方法

• 小分子BRD4/BET抑制劑
  • 第一代BET抑制劑
  • 新一代選擇性BET抑制劑
• BRD4蛋白水解方法
  • 基於PROTAC的BRD4分解器
  • 分子黏合劑分解劑
• 基因靜默策略
  • 基於RNA的基因靜默
  • 基於 CRISPR 的 BRD4標靶化
• 藥物再利用策略
• 針對BRD4的新策略
  • 共用和變構BRD4抑制劑
  • 雙標靶BRD4治療藥物

第5章 疾病生物學與治療證據

• BRD4在癌症中的作用
  • 骨髓惡性腫瘤
  • 固態腫瘤
• 腫瘤學以外領域的機遇
  • 自體免疫疾病與發炎性疾病
  • 微生物感染疾病
  • 心血管疾病

第6章：BRD4標靶治療與聯合治療

• 利用表觀遺傳藥物進行BRD4標靶治療
• 使用蛋白酪氨酸激酶抑制劑的BRD4標靶治療
• 使用 BCL-2 抑制劑的 BRD4標靶治療
• 採用動態療法進行BRD4標靶治療

第7章：BRD4標靶治療的全球臨床試驗概述

• 愛別
• 國家
• 公司
• 適應症
• 優先事項

第8章 按公司、適應症和階段分類的BRD4標靶治療的全球臨床試驗

• 研究
• 臨床前
• 第一階段
• 第一/二期
• 第二階段
• 第三階段

第9章：BRD4標靶治療開發平台

第10章：全球BRD4標靶治療市場趨勢與發展

• 當前市場概況
• 未來發展方向

第11章：全球BRD4標靶治療市場動態

• 市場促進因素與機遇
• 市場挑戰與限制因素

第12章 競爭格局

• DeepCure
• Epigenetix
• Inhalis Therapeutics
• Kainos Medicines
• Mitsubishi Tanabe Pharma Corporation
• Model Medicines
• Opna Bio
• Plexium
• Prazer Therapeutics
• Ranok Therapeutics

BRD4 Targeted Therapies Market Opportunity, Technology Platform, Development Trends & Clinical Trials Insights 2026 Report Findings & Highlights:

• First BRD4 Targeted Approval Expected By 2030
• Emergence Of BRD4 As A Lead BET Target
• Comprehensive Analysis of Novel Therapeutic Strategies Targeting BRD4
• BRD4 Targeting Therapies Clinical Trials Insight: > 20 Therapies In Trials
• Global BRD4 Targeting Therapies Clinical Trials By Company, Indication & Phase
• Technology and Drug Development Platforms Driving Next Generation BRD4 Therapies
• Competitive Landscape

Need For BRD4 Targeted Therapies & Why This Report?

BRD4 targeted therapies is one of the most rapidly evolving, most exciting and promising sub field within both epigenetic drug development and precision oncology landscape. As the crucial master transcriptional regulator controlling tumor growth, proliferation, metastasis, immunity, resistance to treatment, the bromodomain containing protein 4 (BRD4) has become an incredibly exciting target in the treatment of multiple cancer types. Different from existing cancer drug targets modulating specific signaling pathways, BRD4 as a transcriptional hub plays a pivotal role to orchestrate tumor's key oncogenic transcriptional program including MYC driven gene expression and super enhancer function.

The path to the development of BRD4 targeted therapies has evolved from first generation pan BET inhibitors to increasingly refined and selective strategies for increased efficacy and longevity, targeting bromodomains with enhanced precision to induce gene silencing through novel mechanisms including selective BRD4 inhibitors, bromodomain specific molecules, covalent and allosteric BRD4 inhibitors, targeted protein degraders and combination treatments.

This report delivers a thorough analysis of the evolving landscape of BRD4 targeted therapies including scientific rationales, drug development approaches, clinical updates, novel technologies, competitive landscape and the potential commercial future. It provides insights for investors and pharmaceutical companies in identifying key market opportunities, novel technologies, competitive landscape and opportunities for investment, collaboration and portfolio development for the emerging BRD4 targeting therapy market.

Clinical Trials Insight Included In Report

The clinical development plays an important role in evaluating the future prospects of BRD4 targeted treatments. There is no approved treatment directed against BRD4 so far; however, a number of candidates have completed or are ongoing in clinical research for BRD4 targeted therapies in various hematological malignancies and solid tumors. The report analyzes the current pipeline of BRD4 targeted treatment candidates, as well as those in early and advanced stages of clinical research, that target BRD4 and BET inhibitors in diseases such as acute myeloid leukemia, myelofibrosis, lymphomas, prostate cancer, pediatric cancers, and solid tumors.

This report includes extensive research on current clinical trials and studies targeting BRD4, which involve a wide array of indications, patient populations, clinical phase, and treatments. The information provided involves an analysis of BRD4 monotherapy, as well as combination approach, focusing on the use of BRD4 targeted drugs in combination with epigenetic drugs, apoptosis inducers, kinase inhibitors, DNA repair treatment, and immunotherapy. Furthermore, information about the organizations carrying out the research, such as pharmaceutical companies, biopharmaceutical organizations, and academia, is included in this report, giving a clear picture to the readers regarding the sponsors of BRD4 targeted therapies.

Major Companies Active In R&D Of BRD4 Targeted Therapies

In terms of therapeutic landscape, BRD4 involves a wide range of pharmaceutical companies and biotech firms, as well as research organizations involved in the development of BRD4 targeting drugs in various therapeutic fields. The initial efforts of drug development were mainly represented by companies working on BET inhibitors, as evidenced by development of pelabresib, PLX2853, BMS-986158 and ABBV-075 programs, which contributed to clinical knowledge of BRD4 inhibition in hematology and oncology. These early programs laid the groundwork for the clinical relevance of BRD4 and paved the way for new developments in selective and next generation approaches.

The current competitive landscape consists of companies that develop novel BRD4 targeting strategies, including selective BRD4 inhibitors, degradation of BRD4 protein, and combination therapy. Some of these biotech firms include Halda Therapeutics, DeepCure, Model Medicines, and others. In addition, academic institutions provide the foundation of the competitive landscape through the discovery of novel mechanisms of regulation and treatment opportunities for BRD4. It should be noted that increasing number of industry participants, collaborations, and investments of pharmaceutical companies into drug development of BRD4 show commercial potential of this approach to drug development.

Technology Platforms, Collaborations & Agreements

Technological advancements have resulted in the exploration of non-traditional treatment methods that utilize platforms developed by the companies to modulate the targets in a more selective and sustainable manner. Innovative treatment modalities include protein degradation, such as PROTAC and molecular glues, AI enabled drug discovery, RNA silencing, and precision delivery of the compounds. For instance, the RIPTAC(TM) technology of Halda Therapeutics is an innovative platform targeting the disruption of essential cancerous proteins in tumor cells to develop the product called HLD-0915 for treating prostate cancer. These platforms seek to overcome the challenges of traditional BET inhibitors and develop next generation treatments based on BRD4.

Collaborations involving biotech companies, pharmaceuticals, and academic research institutions have continued to boost innovation in this sphere. Collaborations aimed at developing protein degradation, AI enabled drug discovery, biomarker identification, and precise delivery technologies broaden the range of potential uses for BRD4 based therapies. The report evaluates key technological developments, partnerships, licenses, and platform approaches that will shape the future of BRD4 targeting therapy development.

Report Indicating Future Direction Of BRD4 Targeted Therapies

Precision, new modes of action, and expanded applications represent likely themes for BRD4 targeting therapies in the future. Next generation inhibitors that would target either BRD4 or specific bromodomains may allow opening of additional therapeutic windows, whereas degradation technologies may offer greater ability to silence transcription programs regulated by BRD4. Combination technologies may also play a major role in the growth of BRD4 targeting therapies, which may allow complementing conventional anti-cancer drugs and overcoming resistance mechanisms.

In addition to oncology, a growing understanding of BRD4 biology may open up new horizons for BRD4 therapies in inflammatory diseases, cardiovascular disorders, infectious diseases, and other indications that feature abnormal transcription regulation. The convergence of biomarker driven patient selection, advanced drug delivery technologies, and novel therapeutic platforms will define the future direction of BRD4 research and development. The report offers a comprehensive assessment of these opportunities, providing perspectives on scientific advancement, commercial potential, and future positioning of therapies targeting BRD4.

Table of Contents

1. Research Methodology

2. Introduction to BET Family & BRD4 Targeting

• 2.1 Overview Of Epigenetic Drug Targets
• 2.2 Biology & Function Of The BET Protein Family
• 2.3 BET Proteins As Therapeutic Targets
• 2.4 Emergence Of BRD4 As A Lead BET Target
• 2.5 Historical Development Of BRD4-Targeted Therapies

3. Biological Rationale For Targeting BRD4

• 3.1 Structure & Domain Organization Of BRD4
• 3.2 Biological Functions Of BRD4
• 3.3 Role Of BRD4 In Gene Regulation
• 3.4 Role Of BRD4 In Cancer Hallmarks

4. Therapeutic Approaches Targeting BRD4

• 4.1 Small-Molecule BRD4/BET Inhibitors
  • 4.1.1 First-Generation BET Inhibitors
  • 4.1.2 Next-Generation & Selective BET Inhibitors
• 4.2 BRD4 Protein Degradation Approaches
  • 4.2.1 PROTAC-Based BRD4 Degraders
  • 4.2.2 Molecular Glue Degraders
• 4.3 Gene Silencing Strategies
  • 4.3.1 RNA-Based Gene Silencing
  • 4.3.2 CRISPR-Based BRD4 Targeting
• 4.4 Drug Repurposing Strategies
• 4.5 Emerging BRD4-Targeting Strategies
  • 4.5.1 Covalent & Allosteric BRD4 Inhibitors
  • 4.5.2 Dual-Target BRD4 Therapeutics

5. Disease Biology & Therapeutic Rationale

• 5.1 BRD4 in Cancer
  • 5.1.1 Hematological Malignancies
  • 5.1.2 Solid Tumors
• 5.2 Non-Oncology Opportunities
  • 5.2.1 Autoimmune & Inflammatory Diseases
  • 5.2.2 Microbial Infections
  • 5.2.3 Cardiovascular Diseases

6. BRD4 Targeted Therapies Combination Therapeutic Approaches

• 6.1 BRD4 Targeted Therapies With Epigenetic Drugs
• 6.2 BRD4 Targeted Therapies With Tyrosine Kinase Inhibitors
• 6.3 BRD4 Targeted Therapies With BCL-2 Inhibitors
• 6.4 BRD4 Targeted Therapies With Photodynamic Therapy

7. Global BRD4 Targeted Therapies Clinical Trials Overview

• 7.1 By Phase
• 7.2 By Country
• 7.3 By Company
• 7.4 By Indication
• 7.5 By Priority Status

8. Global BRD4 Targeted Therapies Clinical Trials By Company, Indication & Phase

• 8.1 Research
• 8.2 Preclinical
• 8.3 Phase-I
• 8.4 Phase-I/II
• 8.5 Phase-II
• 8.6 Phase-III

9. BRD4 Targeted Therapies Development Platforms

10. Global BRD4 Targeted Therapies Market Trend & Developments

• 10.1 Current Market Outline
• 10.2 Future Development Directions

11. Global BRD4 Targeted Therapies Market Dynamics

• 11.1 Market Drivers & Opportunities
• 11.2 Market Challenges & Restraints

12. Competitive Landscape

• 12.1 DeepCure
• 12.2 Epigenetix
• 12.3 Inhalis Therapeutics
• 12.4 Kainos Medicines
• 12.5 Mitsubishi Tanabe Pharma Corporation
• 12.6 Model Medicines
• 12.7 Opna Bio
• 12.8 Plexium
• 12.9 Prazer Therapeutics
• 12.10 Ranok Therapeutics

List of Figures

• Figure 2-1: Overview Of Epigenetic Regulation & Therapeutic Target Classes
• Figure 2-2: Overview Of Epigenetic Machinery
• Figure 2-3: Structural Organization Of BET Proteins
• Figure 2-4: BET Protein-Mediated Recognition Of Histone Acetylation - Mechanism
• Figure 2-5: BET-Dependent Transcriptional Addiction In Cancer
• Figure 2-6: Cancers Associated With BRD4 Dysregulation
• Figure 2-7: BRD4 Therapeutic Strategies - Evolution
• Figure 2-8: BRD4-Targeted Therapy Development - Historical Timeline
• Figure 3-1: BRD4 Protein - Functional Architecture
• Figure 3-2: BRD4 - Integrator Of Multiple Cellular Pathways
• Figure 3-3: BRD4 - Major Biological Functions
• Figure 3-4: BRD4 Coordinates Multiple Levels Of Gene Regulation
• Figure 3-5: BRD4 In The Hallmarks Of Cancer
• Figure 4-1: First-Generation BET Inhibitors - Mechanism & Limitations
• Figure 4-2: Representative First-Generation BET Inhibitors
• Figure 4-3: Evolution Towards Selective BET Inhibitors
• Figure 4-4: BRD4 Degradation Via PROTAC
• Figure 4-5: BRD4 PROTAC Degraders - Advantages
• Figure 4-6: Molecular Glue-Mediated BRD4 Degradation - Mechanism
• Figure 4-7: Molecular Glue Degraders For BRD4 Therapy - Advantages
• Figure 4-8: CRISPRi vs CRISPRa: Bidirectional Control Of BRD4 Expression
• Figure 4-9: CRISPR Technologies For BRD4 Research - Evolution
• Figure 4-10: Challenges Limiting Clinical Translation o&f BRD4 CRISPR Therapy
• Figure 4-11: Drug Repurposing Strategies For BRD4 Targeting - Overview
• Figure 4-12: Next-Generation BRD4-Selective Inhibitors
• Figure 4-13: Covalent BRD4 Inhibition - Mechanism
• Figure 4-14: Canonical vs Non-Canonical BRD4 Binding
• Figure 4-15: Allosteric BRD4 Inhibition - Mechanism
• Figure 4-16: Next-Generation BRD4 Inhibitor Development - Challenges
• Figure 4-17: Dual-Target BRD4 Therapeutics - Concept
• Figure 5-1: CHAMP-1 Phase 1/2 (NCT05487170) Study - Initiation & Completion Year
• Figure 5-2: CA011-023 Phase 1/2 (NCT04817007) Study - Initiation & Completion Year
• Figure 5-3: NCI-2022-04100 Phase 1 (NCT05372640) Study - Initiation & Completion Year
• Figure 5-4: NCI-2020-04495 Phase 1 (NCT04471974) Study - Initiation & Completion Year
• Figure 5-5: NCI-2023-03408 Phase 1 (NCT05950464) Study - Initiation & Completion Year
• Figure 5-6: HLD-0915-ONC-101 Phase 1/2 (NCT06800313) Study - Initiation & Completion Year
• Figure 5-7: Autoimmune & Inflammatory Diseases - Therapeutic Applications Of BRD4 Inhibition
• Figure 5-8: BRD4 As A Host-Directed Therapeutic Target In Microbial Infections
• Figure 5-9: BRD4 As A Central Regulator Of Cardiovascular Diseases
• Figure 6-1: Rationale For Combining BRD4 Inhibitors With Epigenetic Therapies
• Figure 6-2: BRD4-TKIs Combination Therapy - Rationale
• Figure 6-3: BRD4-BCL-2 Combination Therapy - Rationale
• Figure 6-4: BRD4 Inhibition & Photodynamic Therapy Combination - Biological Effects
• Figure 7-1: Global - Number Of BRD4 Targeted Therapies In Clinical Trials By Phase, 2026
• Figure 7-2: Global - Number Of BRD4 Targeted Therapies Clinical Trials By Country, 2026
• Figure 7-3: Global - Number Of BRD4 Targeted Therapies Clinical Trials By Company, 2026
• Figure 7-4: Global - Number Of BRD4 Targeted Therapies Clinical Trials By Indication, 2026
• Figure 7-5: Global - Number Of BRD4 Targeted Therapies Clinical Trials By Priority Status, 2026
• Figure 9-1: Vyne Therapeutics - BET Inhibitor Platform
• Figure 10-1: BRD4-Targeted Therapeutics - Future Opportunities
• Figure 11-1: Global BRD4 Targeting Therapies Market - Favorable Parameters

List of Tables

• Table 2-1: Classification Of Epigenetic Regulators
• Table 2-2: BET Family Members & Tissue Distribution
• Table 2-3: BET Proteins As Drug Targets - Advantages & Challenges
• Table 2-4: Major Discoveries That Established BRD4 As The Lead BET Target
• Table 3-1: BRD4-Mediated Gene Regulation Mechanisms
• Table 3-2: Effect Of BRD4 Inhibition On Cancer Hallmarks
• Table 4-1: First-Generation BET Inhibitors - Advantages & Limitations
• Table 4-2: Comparison Of BET Inhibition Strategies
• Table 4-3: PROTAC vs Molecular Glue: Structural & Pharmacological Comparison
• Table 4-4: siRNA vs shRNA vs ASO vs miRNA: Functional Comparison
• Table 4-5: BRD4 Drug Repurposing - Advantages & Limitations
• Table 4-6: Dual BRD4 Therapeutics - Advantages & Challenges
• Table 5-1: BRD4-Targeted Antimicrobial Therapy - Advantages & Challenges
• Table 6-1: Representative BRD4-Photodynamic Therapy Strategies
• Table 11-1: Global BRD4 Targeting Therapies Market -Challenges & Potential Solutions